Messenger Ribonucleic Acid, mRNA:

Market Insight, CDMO Pricing and Competitor Benchmarking

Over 900 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to craft Nice Insight’s first Messenger RNA (mRNA): Market Insight, CDMO Pricing and Competitor Benchmarking study.

About This Report

• The first edition of our mRNA report is the first published study of CDMO Pricing for mRNA production.

• This is the first study of the clinical trial landscape for RNA modalities. The clinical trial analysis covers mRNA and synthetic RNA. We breakdown the correlation of RNA modality with their target indications. 

• We provide projections for ongoing growth of therapeutics entering the clinic and expecting approval, which will drive the need for manufacturing and analytical services.

• We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.

• We obtained input from subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.

Study Methodology

• For the first edition of Nice Insight’s messenger RNA report we have compiled up-to-date primary data, proprietary data, and a survey of secondary data from the published literature and industry databases to create a comprehensive outsourced development and manufacturing of mRNA. The quantitative research that we performed is supplemented by direct interviews conducted with multiple subject matter experts in diverse roles within the sector to obtain qualitative perspectives on the dynamics of the space.

• To build a dataset of RNA-based clinical trials, we started with a dataset of every clinical trial published at ClinicalTrials.gov since January 1, 2013. We probed the dataset in three different types of queries to pull out all clinical trials, and built custom macros to mine and curate the data. To our knowledge this is the first such study of the landscape that is published.

• The data from over 1,900 trials was curated to focus only on the investigation of RNA therapeutics, and separated them from classical viral vector-based gene therapies and ex vivo gene-modified cell therapies. This dataset was used to analyze innovators, funding, modalities, and more.

• The content included here reflects in total over 500 hours of dedicated research, interviews, analysis, and composition, both to develop the first such pricing study and survey of mRNA clinical trials published.

• A team comprising six (6) Ph.D.-level experts collaborated with a group of 25+ existing clients representing CDMOs within the mRNA manufacturing and development sector to understand benchmarks, current challenges, and the future of the industry.

• We conducted a comprehensive survey of the key players in the sector to develop informative mRNA CDMO profiles for comparison.

• Our staff with over 45 years of industry experience worked for over four months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.

• We interviewed SMEs representing manufacturing, innovators, and other operations at small and medium-sized CDMOs to discuss pricing for contract development and manufacturing services. We focused on understanding how the manufacturers are addressing the challenges of funding, scale variability, and regulatory uncertainty to serve their clients and what are the drivers of their pricing decisions.